Center for AIDS Research

Funding Opportunities


RFA-AI-13-055: Pilot Clinical Trials to Eliminate the Latent HIV Reservoir (U01). Application Due Date: July 15, 2014. Link:
This Funding Opportunity Announcement (FOA) solicits applications for support of pilot clinical trials to evaluate interventions aimed at the elimination of the HIV reservoir in HIV-infected adults who are on suppressive antiretroviral therapy. It is expected that the trials will be fully integrated with laboratory-based analytical tools to detect and measure elimination of latently-infected cells both in blood and in tissue.
RFA-HL-14-023: Clinical Research in the Prevention, Diagnosis, and Treatment of HIV-Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01). Application Due Dates: May 8, 2014; September 9, 2014; and January 8, 2015. Link:
This Funding Opportunity Announcement (FOA) invites clinical research project grant (R01) applications on the prevention, diagnosis, and treatment of HIV-related heart, lung, and/or blood (HLB) diseases in adults and children. Proposed projects may utilize various approaches such as observational studies; quasi-experimental designs; and single-center, pilot trials. Whenever possible, investigators are strongly encouraged to leverage existing infrastructure such as clinical cohorts, biological specimens and imaging banks. The goal of this FOA is to address major scientific gaps in characterizing, preventing, diagnosing, or treating HIV-related HLB diseases and foster multi-disciplinary collaborations among investigators.
RFA-HL-14-024: Basic Research in the Pathogenesis of HIV-Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01/R21). Application Due Dates: May 8, 2014; September 9, 2014; and January 8, 2015. Link:
This Funding Opportunity Announcement (FOA) invites basic research project grant (R01) applications to investigate the fundamental mechanisms underlying the pathogenesis of HIV-related heart, lung, and/or blood (HLB) diseases alone and in the context of antiretroviral therapy (ART). Investigations may be conducted on various primary cell types, biospecimens, computational models, and animal models, particularly those used for HIV research. The goal is to provide the critical basic science foundation and guide the design of new therapeutic approaches for HIV-related HLB conditions in adults and children.
PA-13-377: Research on Malignancies in the Context of HIV/AIDS (R01/R21). Application Due Dates: May 8, 2014; September 9, 2014; and January 8, 2015. Link:
This funding opportunity announcement (FOA) encourages Research Project Grant (R01) applications from institutions/ organizations that propose to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying Human Immunodeficiency (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS). The NCI and NIDCR encourage research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in diverse populations. This FOA encourages research efforts that will (i) provide information on the clinical outcomes of such cancers in the HIV-infected population and (ii) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.
PAR -13-349: Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01). Application Due Dates: January 8, 2015; January 8, 2016. Link:
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention. Applications may propose treatment or prevention products delivered using sustained release platforms (oral, injection, implant or direct delivery to HIV target mucosa) that will provide a minimum of one week (treatment) or one month (prevention) of efficacy/protection.
PAR-13-267: Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01). Application Due Dates: January 8, 2015; January 8, 2016. Link:
The National Institute of Mental Health invites research grant applications to develop innovative programs to advance therapeutics for NeuroAIDS. This Funding Opportunity Announcement (FOA) will support research programs that will advance central nervous system (CNS)-focused therapeutic approaches to: a) address HIV-associated neurocognitive disorders in HIV-infected individuals on highly active anti-retroviral therapy (HAART), b) eradicate persistent HIV-1 from the CNS during chronic infection, c) prevent establishment of HIV-1 in the brain during early infection, and d) assess the potential for CNS toxicity using HAART or candidate drugs that are currently in clinical studies to eradicate HIV-1. Studies to create or adapt existing animal models of HIV-1 infection in the CNS may be proposed to enable assessment of novel HIV CNS-focused therapeutic candidates. Multi-disciplinary, multi-project programs that are focused on improving neurocognition in HIV-infected persons are encouraged. A well defined, synergistic and milestone-driven plan for discovery, preclinical, and/or early clinical hypothesis-driven research should be presented. Public-private partnerships are encouraged but not required.

 CFAR Microgrant Program 

The goal of funding by CFAR microgrants to rapidly respond to the needs of CFAR investigators or Einstein investigators interested in expanding into HIV/AIDS research by supporting highly focused and goal-driven experiments designed to achieve small but practical end points to help generate data needed to submit or revise a manuscript or to submit a CFAR pilot grant or externally-funded grant. Examples of appropriate use of this funding mechanism is to purchase critical reagents needed for experiments or to support the use of CFAR or Einstein Cores. The maximum amount of funding provided is $5,000 and is non-renewable.  Applications can be submitted to Dr. Prasad by anyone at any time and consist of a one page description of the proposed experiment describing how the proposed work would rapidly lead to publication or grant application, a budget justification and a NIH CV of the applicant and relevant personnel. Applications are rapidly reviewed by a standing committee chaired by Dr. Vinayaka Prasad, Developmental Core Director and Associate Director and the CFAR Director and CFAR Associate Director.  

Einstein-Montefiore CFAR Pilot Project Funding Opportunity Announcement: 

HIV/AIDS-related pilot projects- TBA.    


Click here to log in